LifeMD, Inc.: financial analysis
Ratios worked out from 10 fiscal years of LifeMD, Inc.'s statements, compared with 9 companies in Retail - Pharmacy.
LifeMD, Inc. scorecard#
Passes 18 of the 26 checks that could be worked out: strongest in growth (6 of 6), weakest in valuation (3 of 6). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation3 of 6
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median6.1×Price to book 6.1× against Healthcare's median of 3.0×.
- ✓Price to sales below its peers' median0.6×Price to sales 0.6× against Healthcare's median of 3.7×.
- ✓Free cash flow yield above 5%5.7%Free cash flow is 5.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- ✓The price assumes slower growth than the last three years'-0.9%The price assumes -0.9% a year for ten years; revenue grew 17.7% a year over the last three.
Growth6 of 6
- ✓Revenue grew in the newest year25.4%Revenue up 25.4% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years17.7%17.7% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median17.7%17.7% a year against Retail - Pharmacy's median of 0.4% (6 companies).
- ✓Earnings per share grew in the newest year0.25 vs -0.60Diluted EPS 0.25 in fiscal 2025 against -0.60 the year before (report's currency).
- ✓Net income higher than five years earlier$14 M$14 M in fiscal 2025 against -$59 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability3 of 5
- ✓Profitable in the newest year$14 MNet income $14 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-4.0%-4.0% against Retail - Pharmacy's median of -2.4% (7 companies).
- ✓Return on equity above 15%310.3%310.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-4.0%-4.0% in fiscal 2025 against -36.5% in 2022.
Financial health2 of 4
- ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.14 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-5.6×Operating income -5.6 times interest in fiscal 2025.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-0.90Z-score -0.90 (distress zone) for fiscal 2025.
Shareholder returns4 of 5
- ✓Pays a dividendYesPaid dividends in fiscal 2025.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- ✓Dividends under 75% of net income21.7%Dividends were 21.7% of net income in fiscal 2025.
- ✗Share count up no more than 2% in a year9.6%Diluted shares up 9.6% in fiscal 2025.
- ✓Dividends and buybacks above 3% of the market value3.0%Dividends and buybacks were 3.0% of the market value.
- ✓Free cash flow covers dividends and buybacks$6 MFree cash flow $6 M against $3 M paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Retail - Pharmacy, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Strengths
- Revenue has grown 8 years in a row.
Worth a look
- The share count rose 9.6% in the year.
- Operating income covers the interest bill only -5.6 times.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profityes
- Operations brought in cashyes
- Return on assets roseyes
- Cash from operations exceeds profitno
- Long-term debt fell against assetsnot on file
- Current ratio roseyes
- No new shares issuedno
- Gross margin roseno
- Asset turnover roseyes
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.09 | × 1.2 | 0.10 |
| Retained earnings to assets | -3.67 | × 1.4 | -5.14 |
| Operating income to assets | -0.12 | × 3.3 | -0.40 |
| Market value to liabilities | 2.48 | × 0.6 | 1.49 |
| Revenue to assets | 3.05 | × 1 | 3.05 |
Where the return on equity comes from
The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 85.7% | 86.2% | 87.6% | 84.3% | 80.6% | 22.6% | 100% | |
| Operating margin | -4.0% | -13.2% | -9.5% | -36.5% | -58.5% | -2.4% | 33% | |
| Net margin | 7.4% | -13.8% | -13.5% | -38.3% | -65.6% | -1.4% | 100% | |
| Return on equity | 310.3% | — | — | — | -595.9% | -49.7% | 100% | |
| Return on assets | 20.6% | -31.8% | -49.0% | -120.5% | -192.4% | -9.7% | 100% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 25.4% | 1.5% | 28.2% | 28.2% | 149.1% | 8.3% | 86% | |
| Revenue growth, 3 years a year | 17.7% | 18.6% | 59.9% | 112.1% | 123.5% | 0.4% | 100% | |
| Revenue growth, 5 years a year | 39.1% | 65.5% | 78.9% | 100.4% | 77.7% | 5.8% | 80% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Interest cover | -5.64× | -9.36× | -5.57× | -33.95× | -17.98× | — | — | |
| Current ratio | 1.14× | 0.78× | 1.22× | 0.36× | 1.97× | 1.14× | 50% | |
| Equity share of assets | 28.8% | -11.9% | 6.0% | -44.4% | 45.6% | 28.8% | 50% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $6 M | $16 M | $9 M | $-23 M | $-33 M | $-16 M | 67% | |
| Free cash flow margin | 3.3% | 10.4% | 5.7% | -19.6% | -35.9% | -0.3% | 100% | |
| Cash conversion | 57.7% | — | — | — | — | — | — | |
| Capital spending share of revenue | 1.0% | 0.9% | 0.1% | 0.3% | 0.3% | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 2.78× | 2.30× | 3.63× | 3.15× | 2.93× | 2.06× | 86% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Cash conversion
- Cash from operations as a share of net income. Only when the year was profitable.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Dividend yield
- Dividends paid in the fiscal year as a share of today's market value.
- Buyback yield
- Shares bought back in the fiscal year as a share of today's market value.
- Shareholder yield
- Dividends plus buybacks as a share of today's market value.
- Dividend payout
- Dividends paid as a share of net income. Only when the year was profitable.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).